Annals of Surgical Oncology

, Volume 14, Issue 2, pp 719–729 | Cite as

Anaplastic Thyroid Carcinoma: Expression Profile of Targets for Therapy Offers New Insights for Disease Treatment

  • Sam M. Wiseman
  • Hamid Masoudi
  • Paddy Niblock
  • Dmitry Turbin
  • Ashish Rajput
  • John Hay
  • Samuel Bugis
  • Douglas Filipenko
  • David Huntsman
  • Blake Gilks



Anaplastic thyroid cancer is an endocrine malignancy. Its rare and rapidly lethal disease course has made it challenging to study. Little is known regarding the expression by anaplastic tumors of molecular targets for new human anticancer agents that have been studied in the preclinical or clinical setting. The objective of this work was to evaluate the expression profile of anaplastic thyroid tumors for molecular targets for treatment.


Of the 94 cases of anaplastic thyroid cancers diagnosed and treated in British Columbia, Canada over a 20-year period (1984–2004), 32 cases (34%) had adequate archival tissue available for evaluation. A tissue microarray was constructed from these anaplastic thyroid tumors and immunohistochemistry was utilized to evaluate expression of 31 molecular markers. The markers evaluated were: epidermal growth factor receptor (EGFR), HER2, HER3, HER4, ER, PR, uPA-R, clusterin, E-cadherin, β-catenin, AMF-R, c-kit, VEGF, ILK, aurora A, aurora B, aurora C, RET, CA-IX, IGF1-R, p53, MDM2, p21, Bcl-2, cyclin D1, cyclin E, p27, calcitonin, MIB-1, TTF-1, and thyroglobulin.


A single tumor with strong calcitonin expression was identified as a poorly differentiated medullary carcinoma and excluded from the study cohort. The mean age of the anaplastic cohort was 66 years; 16 patients (51%) were females, and the median patient survival was 23 weeks. A wide range in molecular marker expression was observed by the anaplastic thyroid cancer tumors (0–100%). The therapeutic targets most frequently and most strongly overexpressed by the anaplastic tumors were: β-catenin (41%), aurora A (41%), cyclin E (67%), cyclin D1 (77%), and EGFR (84%).


Anaplastic thyroid tumors exhibit considerable derangement of their cell cycle and multiple signal transduction pathways that leads to uncontrolled cellular proliferation and the development of genomic instability. This report is the first to comprehensively evaluate a panel of molecular targets for therapy of anaplastic thyroid cancer and supports the development of clinical trials with agents such as cetuximab, small-molecule tyrosine kinase inhibitors, and aurora kinase inhibitors, which may offer new hope for individuals diagnosed with this fatal thyroid malignancy.


Anaplastic Thyroid, Cancer Targeted therapeutics EGFR 



Dr Wiseman and Dr Huntsman are Michael Smith Foundation for Health Research Scholars.


  1. 1.
    O’Neill JP, O’Neill B, Condron C, et al. Anaplastic (undifferentiated) thyroid cancer: improved insight and therapeutic strategy into a highly aggressive disease. J Laryngol Otol 2005; 119:585–591PubMedCrossRefGoogle Scholar
  2. 2.
    Are C, Shaha AR. Anaplastic thyroid carcinoma: biology, pathogenesis, prognostic factors, and treatment approaches. Ann Surg Oncol 2006; Epub ahead of printGoogle Scholar
  3. 3.
    Ain KB. Anaplastic thyroid carcinoma: a therapeutic challenge. Semin in Surg Oncol 1999; 16:64–69CrossRefGoogle Scholar
  4. 4.
    Tennvall J, Lundell G, Wahlberg P, et al. Anaplastic thyroid carcinoma: three protocols combining doxorubicin, hyperfractionated radiotherapy and surgery. Br J Cancer 2002; 86:1848–1853PubMedCrossRefGoogle Scholar
  5. 5.
    Crevoisier RD, Baudin E, Bachelot A, et al. Combined treatment of anaplastic thyroid carcinoma with surgery, chemotherapy and hyperfractionated accelerated external radiotherapy. Int J Radiat Oncol Biol Phys 2004; 60:1137–1143PubMedGoogle Scholar
  6. 6.
    Artega CL, Moulder S, Yakes F. HER (erbB) tyrosine kinase inhibitors in the treatment of breast cancer. Semin Oncol 2002; 29:4–10Google Scholar
  7. 7.
    Chung KY, Saltz LB. Antibody-based therapies for colorectal cancer. Oncologist 2005; 10:701–709PubMedCrossRefGoogle Scholar
  8. 8.
    Comis RL. The current situation: erlotinib (Tarceva©) and gefitinib (Iressa©) in non-small cell lung cancer. Oncologist 2005; 10:467–470PubMedCrossRefGoogle Scholar
  9. 9.
    Sanborn RE, Blanke CD. Gastrointestinal stromal tumors and the evolution of targeted therapy. Clin Adv Hematol Oncol 2005; 3:647–657PubMedGoogle Scholar
  10. 10.
    Siegel-Lakhai WS, Beijnen JH, Schellens JHM. Current knowledge and future directions of the selective epidermal growth factor receptor inhibitors erlotinib (Tarceva©) and gefitinib (Iressa©). Oncologist 2005; 10:579–589PubMedCrossRefGoogle Scholar
  11. 11.
    Parker RL, Huntsman DG, Lesack DW, et al. Assessment of interlaboratory variation in the immunohistochemical determination of estrogen receptor status using a breast cancer tissue microarray. Am J Clin Pathol 2002; 117:723–728PubMedCrossRefGoogle Scholar
  12. 12.
    Liu CL, Prapong W, Natkunam Y, et al. Software tools for high-throughput analysis and archiving of immunohistochemistry staining data obtained with tissue microarrays. Am J Pathol 2002; 161:1557–1565PubMedGoogle Scholar
  13. 13.
    Wiseman S, Loree TR, Rigual NR, et al. Anaplastic transformation of thyroid cancer: review of clinical, pathologic, and molecular evidence provides new insights into disease biology and future therapy. Head Neck 2003; 25:662–670PubMedCrossRefGoogle Scholar
  14. 14.
    McIver B, Hay ID, Giuffrida DF, et al. Anaplastic thyroid carcinoma: a 50-year experience at a single institution. Surgery 2001; 130:1028–1034PubMedCrossRefGoogle Scholar
  15. 15.
    Venkatesh YS, Ordonez NG, Schultz PN, et al. Anaplastic carcinoma of the thyroid. A clinicopathologic study of 121 cases. Cancer 1990; 66:321–330PubMedCrossRefGoogle Scholar
  16. 16.
    Heldin NE, Westermark B. The molecular biology of the human anaplastic thyroid carcinoma cell. Thyroidology 1991; 3:127–131PubMedGoogle Scholar
  17. 17.
    Hoffmann S, Wunderlich A, Celik I, et al. Paneling human thyroid cancer cell lines for candidate proteins for targeted anti-angiogenic therapy. J Cell Biochem 2006; Epub ahead of printGoogle Scholar
  18. 18.
    Lewin, Genes VII. (2000) New York: Oxford University Press, p 875Google Scholar
  19. 19.
    Onda M, Emi M, Yoshida A, et al. Comprehensive gene expression profiling of anaplastic thyroid cancers with cDNA microarrary of 25 344 genes. Endo-Rel Cancer 2004; 11:843–854CrossRefGoogle Scholar
  20. 20.
    Ralfkiaer N, Gatter KC, Alcock C, et al. The value of immunocytochemical methods in the differential diagnosis of anaplastic thyroid tumours. Br J Cancer 1985; 52:167–170PubMedGoogle Scholar
  21. 21.
    Holting T, Moller P, Tschahargane C, et al. Immunohistochemical reclassification of anaplastic carcinoma reveals small and giant cell lymphoma. World J Surg 1990; 14:291–294PubMedCrossRefGoogle Scholar
  22. 22.
    Ensinger C, Spizzo G, Moser P, et al. Epidermal growth factor receptor as a novel therapeutic target in anaplastic thyroid carcinomas. Ann NY Acad Sci 2004; 1030:69–77PubMedCrossRefGoogle Scholar
  23. 23.
    Rosai J. Immunohistochemical markers of thyroid tumors: significance and diagnostic applications. Tumori 2003; 89:517–519PubMedGoogle Scholar
  24. 24.
    Ordonez NG, El-Naggar AK, Hickey RC, et al. Anaplastic thyroid carcinoma. Immunocytochemical study of 32 cases. Am J Clin Pathol 1991; 96:15–24PubMedGoogle Scholar
  25. 25.
    Lam KY, Lo CY, Chan KW, et al. Insular and anaplastic carcinoma of the thyroid: a 45-year comparative study at a single institution and a review of the significance of p53 and p21. Ann Surg 2000; 231:329–338PubMedCrossRefGoogle Scholar
  26. 26.
    Erickson LA, Jin L, Wollan PC, et al. Expression of p27kip1 and Ki-67 in benign and malignant thyroid tumors. Mod Pathol 1998; 11:169–174PubMedGoogle Scholar
  27. 27.
    Urrutiocechea A, Smith IE, Dowsett M. Proliferation marker Ki-67 in early breast cancer. J Clin Oncol 2005; 23:7212–7220CrossRefGoogle Scholar
  28. 28.
    Ross JS, Gray GS. Targeted therapy for cancer: the HER-2/neu and Herceptin story. Clin Leadersh Manag Rev 2003; 17:333–340PubMedGoogle Scholar
  29. 29.
    Ensinger C, Prommegger R, Kendler D, et al. Her2/neu expression in poorly differentiated and anaplastic thyroid carcinomas. Anticancer Res 2003; 23:2349–2353PubMedGoogle Scholar
  30. 30.
    Hiasa Y, Nishioka H, Kitahori Y, et al. Immunohistochemical analysis of estrogen receptors in 313 paraffin section cases of human thyroid tissue. Oncology 1993; 50:132–136PubMedCrossRefGoogle Scholar
  31. 31.
    Younes MN, Kim S, Yigitbasi OG, et al. Integrin-linked kinase is a potential therapeutic target for anaplastic thyroid cancer. Mol Cancer Ther 2005; 4:1146–1156PubMedCrossRefGoogle Scholar
  32. 32.
    Vella V, Sciacca L, et al. The IGF system in thyroid cancer: new concepts. Mol Pathol 2001; 54:121–124PubMedCrossRefGoogle Scholar
  33. 33.
    Brabant G, Hoang-Vu C, Cetin Y, et al. E-cadherin: a differentiation marker in thyroid malignancies. Cancer Res 1993; 53:4987–4993PubMedGoogle Scholar
  34. 34.
    Tallini G, Santoro M, Helie M, et al. RET/PTC oncogene activation defines a subset of papillary thyroid carcinomas lacking evidence of progression to poorly differentiated or undifferentiated tumor phenotypes. Clin Cancer Res 1998; 4:287–294PubMedGoogle Scholar
  35. 35.
    Sorrentino R, Libertini S, Pallante PL, et al. Aurora B overexpression associates with the thyroid carcinoma undifferentiated phenotype and is required for thyroid carcinoma cell proliferation. J Clin Endocrinol Metab 2005; 90:928–935PubMedCrossRefGoogle Scholar
  36. 36.
    Podtcheko A, Ohtsuru A, Tsuda S, et al. The selective tyrosine kinase inhibitor, ST1571, inhibits growth of anaplastic thyroid cancer cells. J Clin Endocrinol Metab 2003; 88:1889–1896PubMedCrossRefGoogle Scholar
  37. 37.
    Dziba JM, Ain KB. Imatinib mesylate (Gleevec;STI571) monotherapy is ineffective in suppressing human anaplastic thyroid carcinoma cell growth in vitro. J Clin Endocrinol Metab 2004; 89:2127–2135PubMedCrossRefGoogle Scholar
  38. 38.
    Schwartz GK, Shah MA. Targeting the cell cycle: a new approach to cancer therapy. J Clin Oncol 2005; 23:9408–9421PubMedCrossRefGoogle Scholar
  39. 39.
    Yoshida A, Fukazawa M, Ushio H, et al. Study of cell kinetics in anaplastic thyroid carcinoma transplanted to nude mice. J Surg Oncol 1989; 42:1–4CrossRefGoogle Scholar
  40. 40.
    Wang S, Lloyd RV, Hutzler MJ, et al. The role of cell cycle regulatory protein, cyclin D1, in the progression of thyroid cancer. Pathology 2000; 13:882–887Google Scholar
  41. 41.
    Bargonetti J, Manfredi JJ. Multiple roles of the tumor suppressor p53. Curr Opin Oncol 2002; 14:86–91PubMedCrossRefGoogle Scholar
  42. 42.
    Moretti F, Farsetti A, Soddu S, et al. p53 re-expression inhibits proliferation and restores differentiation of human thyroid anaplastic carcinoma cells. Oncogene 1997; 14:729–740PubMedCrossRefGoogle Scholar
  43. 43.
    Blagosklonny MV, Giannakakou P, Wojtowicz M, et al. Effects of p53-expressing adenovirus on the chemosensitivity and differentiation of anaplastic thyroid cancer cells. J Clin Endocrinol Metab 1998; 83:2516–2522Google Scholar
  44. 44.
    Fagin JA, Tang SH, Zeki K, Di Lauro R, Fusco A, Gonsky R. Reexpression of thyroid peroxidase in a derivative of an undifferentiated thyroid carcinoma cell line by introduction of wild-type p53. Cancer Res 1996; 56:765–771Google Scholar
  45. 45.
    Buolamwini JK, Addo J, Kamath S, et al. Small molecule antagonists of the MDM2 oncoprotein as anticancer agents. Curr Cancer Drug Targets 2005; 5:57–68PubMedCrossRefGoogle Scholar
  46. 46.
    Kim R, Tanabe K, Uchida Y, et al. Effect of Bcl-2 antisense oligonucleotide on drug-sensitivity in association with apoptosis in undifferentiated thyroid carcinoma. Int J Mol Med 2003; 11:799–804PubMedGoogle Scholar
  47. 47.
    Dziba JM, Marcinek R, et al. Combretastatin A4 phosphate has primary antineoplastic activity against human anaplastic thyroid carcinoma cell lines and xenograft tumors. Thyroid 2002; 12:1063–1070PubMedCrossRefGoogle Scholar
  48. 48.
    Straight AM, Oakley K, Moores R, et al. Aplidin reduces growth of anaplastic thyroid cancer xenografts and the expression of several angiogenic genes. Cancer Chemother Pharmacol 2006; 57:7–14PubMedCrossRefGoogle Scholar
  49. 49.
    Schoenberger J, Grimm D, Kossmehl P, et al. Effects of PTK787/ZK222584, a tyrosine kinase inhibitor, on the growth of a poorly differentiated thyroid carcinoma: an animal study. Endocrinology 2004; 145:1031–1038PubMedCrossRefGoogle Scholar
  50. 50.
    Kim S, Yazici YD, Barber S, et al. Growth inhibition of orthotopic anaplastic thyroid carcinoma xenografts in nude mice by PTK787/ZK222584 and CPT-11. Head Neck 2006; Epub ahead of printGoogle Scholar
  51. 51.
    Bauer AJ, Terrell R, Doniparthi NK, et al. Vascular endothelial growth factor monoclonal antibody inhibits growth of anaplastic thyroid cancer xenografts in nude mice. Thyroid 2002; 12:953–960PubMedCrossRefGoogle Scholar
  52. 52.
    Cardones AR, Banez LL. VEGF inhibitors in cancer therapy. Curr Pharm Des 2006; 12:387–394PubMedCrossRefGoogle Scholar
  53. 53.
    Kim SJ, Shiba E, Taguchi T, et al. uPA receptor expression in benign and malignant thyroid tumors. Anticancer Res 2002; 22:387–393PubMedGoogle Scholar
  54. 54.
    Rono B, Romer J, Liu S, et al. Antitumor efficacy of a urokinase activation-dependent anthrax toxin. Mol Cancer Ther 2006; 5:89–96PubMedCrossRefGoogle Scholar
  55. 55.
    Wiseman S, Masoudi H, Niblock P, et al. Derangement of the E-cadherin complex is involved in transformation of differentiated to anaplastic thyroid carcinoma. Am J Surg 2006; in pressGoogle Scholar
  56. 56.
    Green SK, Karlsson MC, Ravetch JV, et al. Disruption of cell–cell adhesion enhances antibody-dependent cellular cytotoxicity: implications for antibody-based therapeutics of cancer. Cancer Res 2002; 62:6891–6900PubMedGoogle Scholar
  57. 57.
    Harrington EA, Bebbington D, Moore J, et al. VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo. Nat Med 2004; 10:262–267PubMedCrossRefGoogle Scholar
  58. 58.
    Matthews N, Visintin C, Hartzoulakis B, et al. Aurora A and B kinases as targets for cancer: will they be selective for tumors? Expert Rev Anticancer Ther 2006; 6:109–120PubMedCrossRefGoogle Scholar
  59. 59.
    Zaczek A, Brandt B, Bielawski KP. The diverse signaling network of EGFR, HER2, HER3 and HER4 tyrosine kinase receptors and the consequences for therapeutic approaches. Histol Histopathol 2005; 20:1005–1015PubMedGoogle Scholar
  60. 60.
    Baselga J, Arteaga CL. Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. J Clin Oncol 2005; 23:2445–2459PubMedCrossRefGoogle Scholar
  61. 61.
    Bergström JD, Westermark B, Heldin NE. Epidermal growth factor receptor signaling activates met in human anaplastic thyroid carcinoma cells. Exper Cell Res 2000; 259:293–299CrossRefGoogle Scholar
  62. 62.
    Kim S, Prichard CN, Younes MN, et al. Cetuximab and irinotecan interact synergistically to inhibit the growth of orthotic anaplastic thyroid carcinoma xenografts in nude mice. Clin Cancer Res 2006; 12:600–607PubMedCrossRefGoogle Scholar
  63. 63.
    Schiff BA, McMurphy AB, Jasser SA, et al. Epidermal growth factor receptor (EGFR) is overexpressed in anaplastic thyroid cancer, and the EGFR inhibitor gefitinib inhibits the growth of anaplastic thyroid cancer. Clin Can Res 2004; 10:8594–8602CrossRefGoogle Scholar
  64. 64.
    Nobuhara Y, Onoda N, Yamashita Y, et al. Efficacy of epidermal growth factor receptor-targeted molecular therapy in anaplastic thyroid cancer cell lines. Br J Cancer 2005; 92:110–116CrossRefGoogle Scholar
  65. 65.
    Broxterman HJ, Georgopapadakou NH. Anticancer therapeutics: “addictive” targets, multi-targeted drugs, new drug combinations. Drug Resistance Updates 2005; 8:183–197PubMedCrossRefGoogle Scholar
  66. 66.
    Kim S, Schiff BA, Yigitbasi OG, et al. Targeted molecular therapy of anaplastic thyroid carcinoma with AEE788. Mol Cancer Ther 2005; 4:632–640PubMedCrossRefGoogle Scholar
  67. 67.
    Kurebayashi J, Yamamoto Y, Tanaka K. Additive antitumor effects of gefitinib and imatinib on anaplastic thyroid cancer cells. Cancer Chemother Pharmacol 2006; Epub ahead of printGoogle Scholar
  68. 68.
    Saltz L. Epidermal growth factor receptor-negative colorectal cancer: is there truly such an entity? Clin Colorectal Cancer 2005; 5:98–100CrossRefGoogle Scholar

Copyright information

© Society of Surgical Oncology 2006

Authors and Affiliations

  • Sam M. Wiseman
    • 1
    • 2
    • 5
  • Hamid Masoudi
    • 1
    • 2
  • Paddy Niblock
    • 3
  • Dmitry Turbin
    • 2
  • Ashish Rajput
    • 2
  • John Hay
    • 3
  • Samuel Bugis
    • 1
  • Douglas Filipenko
    • 4
  • David Huntsman
    • 2
  • Blake Gilks
    • 2
  1. 1.Department of SurgerySt. Paul’s Hospital, University of British ColumbiaVancouverCanada
  2. 2.Genetic Pathology Evaluation Center at the Prostate Research Center of Vancouver General Hospital, British Columbia Cancer Agency, and University of British ColumbiaVancouverCanada
  3. 3.Department of Radiation OncologyBritish Columbia Cancer AgencyVancouverCanada
  4. 4.Department of PathologySt. Paul’s Hospital, University of British ColumbiaVancouverCanada
  5. 5.Department of SurgerySt. Paul’s Hospital, University of British ColumbiaVancouverCanada

Personalised recommendations